BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15893810)

  • 1. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma.
    Parker AS; Cheville JC; Lohse CM; Igel T; Leibovich BC; Blute ML
    Urology; 2005 Jun; 65(6):1090-5. PubMed ID: 15893810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
    Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
    J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
    He X; Wang J; Messing EM; Wu G
    Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.
    Schraml P; Hergovich A; Hatz F; Amin MB; Lim SD; Krek W; Mihatsch MJ; Moch H
    Am J Pathol; 2003 Sep; 163(3):1013-20. PubMed ID: 12937142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
    Kuehn EW; Walz G; Benzing T
    Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
    Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
    Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus.
    Lin F; Shi J; Liu H; Zhang J; Zhang PL; Wang HL; Yang XJ; Schuerch C
    Am J Clin Pathol; 2008 Apr; 129(4):592-605. PubMed ID: 18343787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
    Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
    Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body mass index and von Hippel-Lindau gene mutations in clear-cell renal cancer: Results of the Netherlands Cohort Study on diet and cancer.
    Smits KM; Schouten LJ; Hudak E; Verhage B; van Dijk BA; Hulsbergen-van de Kaa CA; Goldbohm RA; Oosterwijk E; van den Brandt PA
    Ann Epidemiol; 2010 May; 20(5):401-4. PubMed ID: 20382342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
    Di Cristofano C; Minervini A; Menicagli M; Salinitri G; Bertacca G; Pefanis G; Masieri L; Lessi F; Collecchi P; Minervini R; Carini M; Bevilacqua G; Cavazzana A
    Am J Surg Pathol; 2007 Dec; 31(12):1875-81. PubMed ID: 18043042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.